Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2025)

Historic Operating Expenses for CollPlant Biotechnologies (CLGN) over the last 9 years, with Q3 2025 value amounting to $3.3 million.

  • CollPlant Biotechnologies' Operating Expenses fell 2243.8% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 1779.6%. This contributed to the annual value of $16.1 million for FY2024, which is 205.7% down from last year.
  • Per CollPlant Biotechnologies' latest filing, its Operating Expenses stood at $3.3 million for Q3 2025, which was down 2243.8% from $3.2 million recorded in Q2 2025.
  • Over the past 5 years, CollPlant Biotechnologies' Operating Expenses peaked at $4.7 million during Q4 2022, and registered a low of $92000.0 during Q1 2022.
  • Moreover, its 5-year median value for Operating Expenses was $3.9 million (2024), whereas its average is $3.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 9984.33% in 2021, then skyrocketed by 188061.22% in 2024.
  • Quarter analysis of 5 years shows CollPlant Biotechnologies' Operating Expenses stood at $3.6 million in 2021, then surged by 31.02% to $4.7 million in 2022, then decreased by 1.67% to $4.6 million in 2023, then dropped by 15.85% to $3.9 million in 2024, then decreased by 14.25% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $3.2 million for Q2 2025, and $3.5 million during Q1 2025.